AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.